Of those, the three most commonly identified pathogenic mutations in MPN patients involve the epigenetic regulators TET2, ASXL1, and DNMT3A, all present at frequencies above 5% in an unselected MPN population (1). Here, DNMT3A is linked to myeloproliferative neoplasm.